Literature DB >> 24334440

[Integrated screening for HIV, syphilis, and toxoplasmosis among pregnant women in the Central African Republic].

E P Gamba1, W S Nambei1, L Kamandji1.   

Abstract

OBJECTIVE: The aim of this study was to determine the prevalence of syphilis and toxoplasmosis infection in pregnant women in the Central African Republic who were and were not HIV-infected, in the framework of HIV surveillance.
METHODS: This case-control study included 270 HIV(+) and 217 HIV(-) pregnant women among 4 750 women who attended prenatal-care clinics throughout the Central African Republic from November 2011 through January 2012. Blood specimens were collected and serological evidence of HIV1/2 was analyzed by ELISA1 and ELISA2. The Toxoplasma gondii antibody was detected with the Toxo-Hai Fumouze(®) diagnostic kit. A VDRL test was performed to screen for syphilis in all study participants.
RESULTS: Of the 434 samples tested, 33 (7.60%) were positive for syphilis: 21 (9.7%) among HIV(+) and 12 (5.5%) among HIV(-) women (p = 0.1031); 221 (50.90%) were positive for toxoplasmosis: 117 (53.9%) among HIV(+) and 104 (47.9%) among HIV(-) women (p = 0, 2119). Coinfection with HIV, syphilis, and toxoplasmosis was found in 6.00%. No association was found between coinfection and age, parity, and residence area. The rate of syphilis infection was very high in pregnant women living in rural areas (ORcrude = 4.37; 95% CI = 2,11, 9.05).
CONCLUSION: This study showed a high prevalence of toxoplasmosis and syphilis in pregnant women in the Central African Republic, regardless of their HIV infection status. Sexually transmitted infections (STIs) are common in pregnant women living in rural areas. It may be appropriate to include routine serological screening tests to determine of toxoplasmosis, syphilis and HIV in pregnant women in this country.

Entities:  

Keywords:  Central African Republic; HIV; pregnant women; syphilis; toxoplasmosis

Mesh:

Year:  2013        PMID: 24334440     DOI: 10.1684/mst.2013.0256

Source DB:  PubMed          Journal:  Med Sante Trop        ISSN: 2261-3684


  5 in total

1.  Non-malarial infectious diseases of antenatal care in pregnant women in Franceville, Gabon.

Authors:  Irene Pegha Moukandja; Edgard Brice Ngoungou; Guy Joseph Lemamy; Ulrick Bisvigou; Antoine Gessain; Fousseyni S Toure Ndouo; Mirdad Kazanji; Jean Bernard Lekana-Douki
Journal:  BMC Pregnancy Childbirth       Date:  2017-06-12       Impact factor: 3.007

2.  Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis.

Authors:  Ze-Dong Wang; Huan-Huan Liu; Zhan-Xi Ma; Hong-Yu Ma; Zhong-Yu Li; Zhi-Bin Yang; Xing-Quan Zhu; Bin Xu; Feng Wei; Quan Liu
Journal:  Front Microbiol       Date:  2017-03-09       Impact factor: 5.640

3.  Laboratory evaluation of the Chembio Dual Path Platform HIV-Syphilis Assay.

Authors:  Mireille B Kalou; Arnold Castro; Amy Watson; Heather Jost; Stacy Clay; Ye Tun; Cheng Chen; Kevin Karem; John N Nkengasong; Ronald Ballard; Bharat Parekh
Journal:  Afr J Lab Med       Date:  2016-09-15

4.  Better care for babies: the added value of a modified reverse syphilis testing algorithm for the treatment of congenital syphilis in a maternity Hospital in Central African Republic.

Authors:  Oluwakemi F Ogundipe; Rafael Van den Bergh; Behounde Thierry; Kudakwashe C Takarinda; Claude P Muller; Collins Timire; Severine Caluwaerts; Pascale Chaillet; Isabel Zuniga
Journal:  BMC Pediatr       Date:  2019-08-15       Impact factor: 2.125

5.  Highlighting a population-based re-emergence of Syphilis infection and assessing associated risk factors among pregnant women in Cameroon: Evidence from the 2009, 2012 and 2017 national sentinel surveillance surveys of HIV and syphilis.

Authors:  Cyprien Kengne-Nde; Jean de Dieu Anoubissi; Gabriel Loni-Ekali; Celine Nguefeu-Nkenfou; Yasmine Moussa; Arlette Messeh; Joseph Fokam; Albert Zeh-Meka; Denis Snayeul-Wawo; Dorine Tseuko; Marinette Ngo-Nemb; David Kob; Serge-Clotaire Billong; Leonard Bonono; Jean-Bosco Elat
Journal:  PLoS One       Date:  2020-11-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.